Cyclerion Therapeutics, Inc.

NasdaqCM:CYCN Stock Report

Market Cap: US$3.6m

Cyclerion Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure3.8yrs

Recent management updates

Recent updates

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Oct 06

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Mar 03
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 26

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Jun 21

Cyclerion climbs on a series of insider purchases

Jun 08

Cyclerion updates on clinical trial progress at webinar

Apr 28

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Mar 09
Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Jan 28
What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Cyclerion Therapeutics +10.5% after prelim reports

Jan 13

Cyclerion Therapeutics announces promotions

Dec 21

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Dec 20
Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Cyclerion Therapeutics reports Q3 results

Nov 05

CEO

Cyclerion Therapeutics has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Peter Hecht
Director5.6yrsUS$169.80k15%
$ 535.9k
Errol De Souza
Independent Chairman3.6yrsUS$131.08k1.99%
$ 71.0k
Harald H. H. Schmidt
Member of Scientific Advisory Board3.8yrsno datano data
Steven Hyman
Independent Director2.3yrsUS$57.30k0.79%
$ 28.4k
Michael Higgins
Independent Directorless than a yearUS$43.60k0.79%
$ 28.4k
Robert Malenka
Member of Scientific Advisory Board3.8yrsno datano data
Daniela Salvemini
Member of Scientific Advisory Board3.8yrsno datano data
Mark Currie
Chair of Scientific Advisory Boardno dataUS$366.78kno data
Andrew Budson
Member of Clinical Advisory Board3.8yrsno datano data
Eric Smith
Member of Clinical Advisory Board3.8yrsno datano data
M Westover
Member of Clinical Advisory Board3.8yrsno datano data
David Salat
Member of Clinical Advisory Board3.8yrsno datano data

3.8yrs

Average Tenure

69yo

Average Age

Experienced Board: CYCN's board of directors are considered experienced (3.8 years average tenure).